摘要
目的研究地屈孕酮联合二甲双胍治疗多囊卵巢综合征(PCOS)的效果。方法随机选择该院2019年1月—2021年6月收治的80例门诊PCOS患者,随机分为研究组和对照组,各40例。对照组应用地屈孕酮治疗,研究组应用地屈孕酮联合二甲双胍进行治疗,对比两组相关指标情况。结果研究组治疗后T(2.13±0.28)nmol/L、E2(110.62±18.50)pmol/L、LH(9.36±2.15)IU/L、FSH(5.21±0.64)IU/L,均低于对照组,差异有统计学意义(t=2.540、4.849、3.139、10.599,P<0.05);研究组治疗后FINS(9.87±1.12)mU/L、FPG(4.82±0.57)mmol/L、HOMA-IR(3.04±0.31),均低于对照组,差异有统计学意义(t=2.061、2.555、2.435,P<0.05);研究组治疗后TG(1.23±0.15)mmol/L、TC(4.02±0.41)mmol/L、HDL-C(1.63±0.19)mmol/L、LDL-C(2.64±0.25)mmol/L,与对照组比较差异有统计学意义(t=3.348、2.637、3.396、2.864,P<0.05);研究组不良反应发生率10.00%与对照组25.00%比较,差异无统计学意义(χ^(2)=3.117,P>0.05)。结论地屈孕酮联合二甲双胍治疗多囊卵巢综合征显著,可有效降低患者的血清性激素水平,改善糖脂代谢指标和血脂代谢指标,值得使用。
Objective To study the effect of dydrogesterone combined with metformin in the treatment of polycystic ovary syndrome(PCOS).Methods A total of 80 outpatient PCOS patients in the hospital from January 2019 to June 2021 were randomly selected and randomly divided into a study group and a control group,40 cases in each group.The control group was treated with dydrogesterone,and the study group was treated with dydrogesterone combined with metformin After treatment,the relative indicators of the two groups were compared.Results After treatment,T(2.13±0.28)nmol/L,E2(110.62±18.50)pmol/L,LH(9.36±2.15)IU/L,FSH(5.21±0.64)IU/L in the study group were lower than those in the control group,the difference was statistically significant(t=2.540,4.849,3.139,10.599,P<0.05);after treatment in the study group,FINS(9.87±1.12)mU/L,FPG(4.82±0.57)mmol/L,HOMA-IR(3.04±0.31),all lower than the control group,the difference was statistically significant(t=2.061,2.555,2.435,P<0.05);after treatment in the study group TG(1.23±0.15)mmol/L,TC(4.02±0.41)mmol/L,HDL-C(1.63±0.19)mmol/L,LDL-C(2.64±0.25)mmol/L,and the difference was statistically significant compared with the control group(t=3.348,2.637,3.396,2.864,P<0.05);the incidence of adverse reactions in the study group was 10.00%compared with 25.00%in the control group,and the difference was not statistically significant(χ^(2)=3.117,P>0.05).Conclusion Dydrogesterone combined with metformin in the treatment of polycystic ovary syndrome is significant,can effectively reduce the serum sex hormone levels,improve the glucose and lipid metabolism indicators and blood lipid metabolism indicators,and it is worth using.
作者
何金莲
闫俊芳
HE Jinlian;YAN Junfang(Department of Obstetrics and Gynecology,Fuzhou Maternal and Child Health Hospital,Fuzhou,Fujian Province,350000 China)
出处
《中外医疗》
2022年第10期108-111,共4页
China & Foreign Medical Treatment
